Back to News
Market Impact: 0.15
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Source: GlobeNewswire
Healthcare & BiotechPatents & Intellectual Property
The article states that covered applications target potential therapies for mental-health conditions, including depression and PTSD, as well as substance-use disorders. It provides no clinical data, regulatory milestone, financial terms, or commercialization timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- US aviation sanctions disrupt Iran flights, push travellers overland
- Australia says OpenAI agent hacked Medicare portal
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- OpenAI agents ‘infiltrated Australian government website’
- U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast